By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Recordati S.p.A 

Via M. Civitali, 1

Milan    20148  Italy
Phone: 39-02-487871 Fax: 39-02-40073747




Forest  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Digital Gene Technologies  Atherosclerosis

Company News
Recordati CEO Dies; Drug Giant Urgently Names New CEO 8/16/2016 9:57:46 AM
Apricus Biosciences (APRI) Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Spain By Recordati S.p.A 5/6/2015 7:37:10 AM
Recordati S.p.A Finalizes The Second Tranche Of Its Acquisition Of Opalia Pharma In Tunisia 5/27/2014 9:37:15 AM
Prasco Laboratories Announces Authorized Generic Agreement With Recordati S.p.A 5/22/2014 9:35:51 AM
Recordati S.p.A: Sales Growth And Significant Margin Improvement In The First Quarter 2014 5/6/2014 9:13:51 AM
Recordati S.p.A: Shareholders Approve The 2013 Accounts. Dividend EU 0.33 Per Share 4/17/2014 9:43:43 AM
Gebro Pharma Signs A Licensing Agreement With Recordati S.p.A For The Commercialization Of Kentera® In Spain 2/27/2014 8:48:10 AM
Recordati S.p.A : Preliminary 2013 Results Show Significant Growth. Sales +13.7%, Ebit +17.0%, Net Income +12.8%. 2/11/2014 9:21:02 AM
Apricus Biosciences (APRI), Recordati S.p.A Forge Erectile Dysfunction Pact Worth $47 Million 2/10/2014 7:13:04 AM
Recordati S.p.A Board Of Directors Approves 2014 Objectives 1/16/2014 9:06:08 AM